Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

PRX 019

Next Previous
Drug Profile

PRX 019

Alternative Names: PRX-019

Latest Information Update: 26 May 2026

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Prothena
  • Class Antidementias; Monoclonal antibodies; Neuroprotectants
  • Mechanism of Action Undefined mechanism
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Neurodegenerative disorders
  • Preclinical Alzheimer's disease; Amyotrophic lateral sclerosis

Most Recent Events

  • 16 Jan 2026 Prothena Biosciences completes a phase-I clinical trials in Neurodegenerative disorders (In volunteers) in USA (Parenteral), (NCT06699680)
  • 08 Nov 2024 Phase-I clinical trials in Neurodegenerative disorders (In volunteers) in USA (Parenteral), (NCT06699680),
  • 08 Aug 2024 Prothena plans a phase I trial in USA by the end of 2024

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top